MarketCap
Facebook
X
Telegram
Alnylam Pharmaceuticals Income Statement 2025-2007 | ALNY
Brief overview of revenue and earnings at Alnylam Pharmaceuticals
This overview is based on financial performance over the past five years. Alnylam Pharmaceuticals reported revenue of 493 million dollars in 2020 and 3.7 billion dollars by 2025. Overall revenue changed by +653.6%, equal to an annualized rate of about 49.8%. Sales grew at a rate typical of a strong expansion phase.
The five-year change in gross profit reached +625.3%: from $419 million to $3 billion. The relationship between sales and direct costs deteriorated. Gross margin moved from 84.9% to 81.8%. Weakening gross profitability reduces the quality of the top-line trend.
EBITDA changed from −794 million dollars to 557 million dollars (+170.2%). EBITDA underperformed the top-line trend. Comparing the endpoints gives EBITDA margins of −161% and 15%. Higher profitability strengthens the quality of operating growth.
The final result was −$858 million initially and $314 million in the final year. The return to profit marks a meaningful recovery in the final result.
Over the period, capitalization shifted from $17 billion to $40.8 billion (+139.6%). The market broadly confirmed the positive direction of the business.
Summary assessment
The figures do not all move in the same direction. The strongest signals are improving net profitability, positive operating leverage and sales growth. The main areas of concern are pressure from direct costs. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.
Annual Income Statement Alnylam Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
40.8 B | 33.9 B | 18.6 B | 23.7 B | 18.7 B | 17 B | 12.6 B | 8.22 B | 11.9 B | 3.16 B | 5.79 B | 6.97 B | 5.29 B | 1.2 B | 473 M | 647 M | 879 M | - | - |
Shares |
131 M | 128 M | 125 M | 122 M | 118 M | 115 M | 109 M | 101 M | 90.6 M | 85.6 M | 84 M | 74.3 M | 61.6 M | 50.3 M | 42.4 M | 42 M | 41.8 M | - | - |
Historical Prices |
311 | 266 | 149 | 195 | 158 | 148 | 118 | 85 | 120 | 51.6 | 58.6 | 102 | 81.2 | 23.7 | 13.3 | 15.4 | 21 | 28.2 | 15.9 |
Net Income |
314 M | -278 M | -440 M | -1.13 B | -853 M | -858 M | -886 M | -761 M | -491 M | -410 M | -290 M | -360 M | -89.2 M | -106 M | -57.6 M | -43.5 M | -47.6 M | -26.2 M | - |
Revenue |
3.71 B | 2.25 B | 1.83 B | 1.04 B | 844 M | 493 M | 220 M | 74.9 M | 89.9 M | 47.2 M | 41.1 M | 50.6 M | 47.2 M | 66.7 M | 82.8 M | - | - | - | - |
Cost of Revenue |
677 M | 307 M | 268 M | 140 M | 115 M | 74.2 M | 25.1 M | 1.8 M | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | 195 M | 73.1 M | - | - | - | - | - | - | 82.8 M | - | - | - | - |
Operating Income |
502 M | -177 M | -282 M | -785 M | -709 M | -828 M | -939 M | -815 M | -500 M | -425 M | -296 M | -405 M | -92.9 M | -129 M | -54.8 M | -44.1 M | -48.1 M | -27.8 M | - |
Interest Expense |
5.2 M | -181 M | 121 M | 156 M | 143 M | 84.5 M | - | - | -3.02 M | 6.17 M | 76 K | 1.82 M | -47 K | 331 K | -531 K | 1.98 M | 628 K | 872 K | - |
EBITDA |
557 M | -120 M | -228 M | -741 M | -661 M | -794 M | -885 M | -808 M | -487 M | -409 M | -277 M | -172 M | -82.7 M | -54.5 M | -49.7 M | -39.1 M | -42.1 M | -22.1 M | - |
Operating Expenses |
- | - | - | - | - | - | 1.13 B | 888 M | 590 M | 472 M | 337 M | 235 M | 140 M | 130 M | 138 M | 144 M | 149 M | 124 M | - |
General and Administrative Expenses |
1.21 B | 976 M | 796 M | 771 M | 621 M | 588 M | 479 M | 382 M | 199 M | 89.4 M | 60.6 M | 44.5 M | 27.2 M | 43.7 M | 38.3 M | 37.7 M | 39.9 M | 27.1 M | - |
All numbers in USD currency
Quarterly Income Statement Alnylam Pharmaceuticals
| 2026-Q2 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
134 M | 131 M | 131 M | 130 M | 129 M | 129 M | 127 M | 126 M | 126 M | 125 M | 125 M | 124 M | 124 M | 122 M | 121 M | 120 M | 120 M | 119 M | 118 M | 117 M | 116 M | 116 M | 115 M | 113 M | 112 M | 109 M | 109 M | 105 M | 101 M | 101 M | 101 M | 100 M | 96.1 M | 91.8 M | 88.1 M | 86 M | 85.8 M | 85.7 M | 85.5 M | 85.3 M | 84.9 M | 84.6 M | 84.4 M | 82.1 M | 77 M | 76.4 M | 75.8 M | 67.8 M | 62.9 M | 62.4 M | 61.7 M | 59.2 M | 51.8 M | 51.5 M | 51.3 M | 46.2 M | 42.7 M | 42.7 M | 42.4 M | 42.3 M | 42.2 M | 42.1 M |
Net Income |
164 M | 251 M | -66.3 M | -57.5 M | - | -112 M | -16.9 M | -65.9 M | - | 148 M | -276 M | -174 M | - | -406 M | -277 M | -240 M | - | -205 M | -190 M | -200 M | -244 M | -253 M | -179 M | -182 M | -276 M | -209 M | -219 M | -182 M | -211 M | -245 M | -164 M | -141 M | -142 M | -123 M | -118 M | -107 M | -113 M | -104 M | -90.1 M | -103 M | -90.7 M | -76.8 M | -71.8 M | -50.8 M | -21.4 M | -44 M | -44.1 M | -251 M | -32.4 M | -29.7 M | -18.2 M | -9.01 M | -62.2 M | -19.5 M | -13 M | -11.4 M | -14.3 M | -13.2 M | -13.8 M | -16.3 M | -9.63 M | -14.6 M |
Revenue |
1.29 B | 1.25 B | 774 M | 594 M | - | 501 M | 660 M | 494 M | - | 751 M | 319 M | 319 M | - | 264 M | 225 M | 213 M | - | 188 M | 221 M | 178 M | 164 M | 126 M | 104 M | 99.5 M | 71.7 M | 70.1 M | 44.7 M | 33.3 M | 21 M | 2.07 M | 29.9 M | 21.9 M | 37.9 M | 17.1 M | 15.9 M | 19 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.61 M | -1.14 M | -889 K | - | -467 K | -1.01 M | 20.9 M | - | - |
Cost of Revenue |
298 M | 197 M | 142 M | 70.2 M | - | 82 M | 67.3 M | 54.6 M | - | 79.5 M | 75.3 M | 41.4 M | - | 36.5 M | 34 M | 23.5 M | - | 28.1 M | 30.3 M | 23 M | - | 20.8 M | 18.3 M | 13.3 M | - | 5.21 M | 4.33 M | 3.35 M | - | 137 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
231 M | 368 M | -16.2 M | 18.1 M | - | -76.9 M | 48.6 M | -43.4 M | - | 214 M | -230 M | -150 M | - | -258 M | -192 M | -147 M | - | -182 M | -146 M | -186 M | - | -225 M | -199 M | -210 M | - | -216 M | -236 M | -189 M | - | -255 M | -192 M | -147 M | - | -126 M | -120 M | -107 M | - | -107 M | -92.4 M | -110 M | - | -78.3 M | -72.9 M | -52.2 M | - | -45.2 M | -45 M | -269 M | - | -32.2 M | -21.3 M | -9.8 M | - | -18.1 M | -12.1 M | -10.9 M | - | -12.4 M | -13.1 M | -15.7 M | -8.73 M | -11.6 M |
Interest Expense |
273 K | -74.2 M | -6.4 M | -49.7 M | - | -29.5 M | -55.7 M | -14.5 M | - | -57.7 M | -35.4 M | 29 M | - | 41.1 M | 42.6 M | 42.4 M | - | 40.3 M | 33.4 M | 32.5 M | - | 28.7 M | 27.2 M | - | - | - | - | 43 K | - | 2.92 M | 2.21 M | 335 K | - | -433 K | -523 K | -2.91 M | - | 401 K | 229 K | 5.24 M | - | -72 K | -27 K | - | - | 524 K | -77 K | -82 K | - | -12 K | -11 K | 5 K | - | -3 K | -21 K | 191 K | - | -597 K | -16 K | 81 K | 20 K | 43 K |
EBITDA |
259 M | 410 M | - | 32.5 M | - | - | - | -29.9 M | - | - | - | -136 M | - | -228 M | -192 M | -137 M | - | -145 M | -146 M | -174 M | - | -201 M | -183 M | -203 M | - | -205 M | -229 M | -185 M | - | -249 M | -187 M | -144 M | - | -116 M | -114 M | -104 M | - | -94.6 M | -83.8 M | -105 M | - | -64.3 M | -64.2 M | -48.5 M | - | -36.6 M | -39.5 M | -266 M | - | -24.6 M | -16.5 M | -7.68 M | - | -11.1 M | -7.34 M | -8.77 M | - | -8.55 M | -10.5 M | -14.3 M | -5.08 M | -9.24 M |
Operating Expenses |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 222 M | 169 M | 185 M | 143 M | 136 M | 125 M | 133 M | 120 M | 101 M | 117 M | 100 M | 84.7 M | 81.6 M | 70.8 M | 69.7 M | 56.2 M | 52.3 M | 277 M | 40.4 M | 41.2 M | 30 M | 28.4 M | 96.8 M | 34.9 M | 33 M | 31.5 M | 34 M | 33.2 M | 33.7 M | 36.6 M | 36.4 M | 38.2 M |
General and Administrative Expenses |
348 M | 322 M | 323 M | 240 M | - | 221 M | 248 M | 211 M | - | 199 M | 215 M | 184 M | - | 236 M | 170 M | 154 M | - | 142 M | 145 M | 147 M | - | 167 M | 128 M | 127 M | - | 120 M | 113 M | 89.6 M | - | 117 M | 84.7 M | 72.4 M | - | 47.6 M | 45.8 M | 38.5 M | - | 22.4 M | 18 M | 21.1 M | - | 16 M | 14.6 M | 12.7 M | - | 9.9 M | 11.5 M | 8.92 M | - | 6.77 M | 5.78 M | 6.27 M | - | 12.8 M | 11.2 M | 10.4 M | - | 8.96 M | 8.43 M | 10.2 M | 8.93 M | 10.1 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Alnylam Pharmaceuticals (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Canada
China
Britain
France
Israel
Germany
Russia
Belgium
Cayman-islands
